MYC and acute myeloid leukemia: By profiling gene signatures that are regulated by NR4As in Kasumi-1 AML cells (carrying the AML-ETO oncogene), we have shown that NR4As reprogram a subset of gene signatures that distinguish primary human LICs from normal hematopoietic stem cells (HSCs), which includes suppression of a core MYC oncogenic program through direct repression of MYC expression [15].